Events and 6-month cumulative incidences of incident VTE in patients with cancer initiating chemotherapy
| . | Patients, n . | Events, n . | Cumulative incidence, % (95% CI)* . |
|---|---|---|---|
| Overall | 40 218 | 1 000 | 2.5 (2.3-2.6) |
| Khorana risk category | |||
| 0: low risk | 14 250 | 210 | 1.5 (1.3-1.7) |
| 1-2: intermediate risk | 21 565 | 610 | 2.8 (2.6-3.1) |
| ≥3: high risk | 4 403 | 180 | 4.1 (3.5-4.7) |
| Khorana score level | |||
| 1 | 12 856 | 318 | 2.5 (2.2-2.8) |
| 2 | 8 709 | 291 | 3.3 (3.0-3.7) |
| 3 | 3 623 | 141 | 3.9 (3.3-4.6) |
| 4 | 717 | 34 | 4.7 (3.4-6.5) |
| 5-6 | 63 | 5 | 7.9 (2.9-16.2) |
| Guideline threshold | |||
| Score 0-1 | 27 106 | 529 | 2.0 (1.8-2.1) |
| Score ≥2 | 13 112 | 471 | 3.6 (3.3-3.9) |
| . | Patients, n . | Events, n . | Cumulative incidence, % (95% CI)* . |
|---|---|---|---|
| Overall | 40 218 | 1 000 | 2.5 (2.3-2.6) |
| Khorana risk category | |||
| 0: low risk | 14 250 | 210 | 1.5 (1.3-1.7) |
| 1-2: intermediate risk | 21 565 | 610 | 2.8 (2.6-3.1) |
| ≥3: high risk | 4 403 | 180 | 4.1 (3.5-4.7) |
| Khorana score level | |||
| 1 | 12 856 | 318 | 2.5 (2.2-2.8) |
| 2 | 8 709 | 291 | 3.3 (3.0-3.7) |
| 3 | 3 623 | 141 | 3.9 (3.3-4.6) |
| 4 | 717 | 34 | 4.7 (3.4-6.5) |
| 5-6 | 63 | 5 | 7.9 (2.9-16.2) |
| Guideline threshold | |||
| Score 0-1 | 27 106 | 529 | 2.0 (1.8-2.1) |
| Score ≥2 | 13 112 | 471 | 3.6 (3.3-3.9) |
Based on the cumulative incidence function considering death as competing risk.